CN106554322B - Phenazine derivative and application thereof in organic electroluminescent device - Google Patents

Phenazine derivative and application thereof in organic electroluminescent device Download PDF

Info

Publication number
CN106554322B
CN106554322B CN201510640793.8A CN201510640793A CN106554322B CN 106554322 B CN106554322 B CN 106554322B CN 201510640793 A CN201510640793 A CN 201510640793A CN 106554322 B CN106554322 B CN 106554322B
Authority
CN
China
Prior art keywords
changed
formula
dibromophenazine
boronic acid
compound represented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201510640793.8A
Other languages
Chinese (zh)
Other versions
CN106554322A (en
Inventor
范洪涛
李银奎
邵爽
任雪艳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Eternal Material Technology Co Ltd
Guan Eternal Material Technology Co Ltd
Original Assignee
Beijing Eternal Material Technology Co Ltd
Guan Eternal Material Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Eternal Material Technology Co Ltd, Guan Eternal Material Technology Co Ltd filed Critical Beijing Eternal Material Technology Co Ltd
Priority to CN201510640793.8A priority Critical patent/CN106554322B/en
Publication of CN106554322A publication Critical patent/CN106554322A/en
Application granted granted Critical
Publication of CN106554322B publication Critical patent/CN106554322B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/46—Phenazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • H—ELECTRICITY
    • H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10K—ORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K85/00—Organic materials used in the body or electrodes of devices covered by this subclass
    • H10K85/60—Organic compounds having low molecular weight
    • H10K85/615—Polycyclic condensed aromatic hydrocarbons, e.g. anthracene
    • H—ELECTRICITY
    • H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10K—ORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K85/00—Organic materials used in the body or electrodes of devices covered by this subclass
    • H10K85/60—Organic compounds having low molecular weight
    • H10K85/615—Polycyclic condensed aromatic hydrocarbons, e.g. anthracene
    • H10K85/622—Polycyclic condensed aromatic hydrocarbons, e.g. anthracene containing four rings, e.g. pyrene
    • H—ELECTRICITY
    • H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10K—ORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K85/00—Organic materials used in the body or electrodes of devices covered by this subclass
    • H10K85/60—Organic compounds having low molecular weight
    • H10K85/615—Polycyclic condensed aromatic hydrocarbons, e.g. anthracene
    • H10K85/626—Polycyclic condensed aromatic hydrocarbons, e.g. anthracene containing more than one polycyclic condensed aromatic rings, e.g. bis-anthracene
    • H—ELECTRICITY
    • H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10K—ORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K85/00—Organic materials used in the body or electrodes of devices covered by this subclass
    • H10K85/60—Organic compounds having low molecular weight
    • H10K85/649—Aromatic compounds comprising a hetero atom
    • H10K85/654—Aromatic compounds comprising a hetero atom comprising only nitrogen as heteroatom
    • H—ELECTRICITY
    • H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10K—ORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K85/00—Organic materials used in the body or electrodes of devices covered by this subclass
    • H10K85/60—Organic compounds having low molecular weight
    • H10K85/649—Aromatic compounds comprising a hetero atom
    • H10K85/657—Polycyclic condensed heteroaromatic hydrocarbons
    • H10K85/6572—Polycyclic condensed heteroaromatic hydrocarbons comprising only nitrogen in the heteroaromatic polycondensed ring system, e.g. phenanthroline or carbazole

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Electroluminescent Light Sources (AREA)

Abstract

The invention relates to a phenazine derivative, and the compound has a structure shown in a formula (1). The phenazine derivatives of the invention are suitable as ETL materials in electroluminescent displays. The use of the material can effectively reduce the working voltage of the organic electroluminescent device and improve the luminous efficiency of the organic electroluminescent device.
Figure DDA0000815298190000011

Description

Phenazine derivative and application thereof in organic electroluminescent device
Technical Field
The invention belongs to the field of organic electroluminescence, and particularly relates to a phenazine derivative, a phenazine derivative intermediate, a preparation method of the phenazine derivative intermediate, and an application of the phenazine derivative and the phenazine intermediate in an electron transport material.
Background
The electron transport material traditionally used in electroluminescent devices is Alq3However, Alq3Has a low electron mobility ratio (approximately at 10)-6cm2Vs). In order to improve the electron transport properties of electroluminescent devices, researchers have made a great deal of exploratory work.
LG chemistry in chinese patent specification CN 101003508A reports a series of pyrene derivatives as electron transporting and injecting materials in electroluminescent devices to improve the luminous efficiency of the devices. FFF-Blm4 (J.Am.chem.Soc.; (Communication); 2008; 130 (11); 3282-. Kodak in U.S. patents (publication nos. US 2006/0204784 and US 2007/0048545) mentioned a hybrid electron transport layer formed by doping one material with a low LUMO level material with another electron transport material with a low device operating voltage and other materials such as metallic materials. Devices based on such hybrid electron transport layers provide improved device efficiency, but increase the complexity of the device fabrication process, which is detrimental to OLED cost reduction. The stable and efficient electron transport material and/or electron injection material are/is developed, so that the device lighting and working voltage is reduced, the device efficiency is improved, the device service life is prolonged, and the method has important practical application value.
Disclosure of Invention
The invention aims to provide a novel phenazine derivative which can be used in the field of organic electroluminescent display. In particular, the compounds can be used as electron transport materials in organic electroluminescent displays.
The use of the material can effectively reduce the working voltage of the organic electroluminescent device and improve the luminous efficiency of the organic electroluminescent device.
In order to achieve the purpose, the technical scheme adopted by the invention is as follows:
a phenazine derivative having a structure represented by formula (1):
Figure BDA0000815298170000011
wherein: ar (Ar)1And Ar2The same or different, are respectively and independently selected from H, halogen and substituted or unsubstituted C4-C30Aryl ring radical of (2), substituted or unsubstituted C4-C30Heteroaryl ring radical, substituted or unsubstituted C4-C30Condensed ring aryl, substituted or unsubstituted C4-C30Fused heterocyclic aryl, substituted or unsubstituted alkyl, cycloalkyl, cyano, arylAromatic secondary amine groups, aliphatic secondary amine groups, substituted or unsubstituted carbazol-9-yl groups, aromatic and aliphatic substituted pyridyl groups, or benzimidazolyl substituted phenyl groups; ar (Ar)1And Ar2Not simultaneously from H.
Preferably, the formula (1) is a structure represented by formula (2) and formula (3):
Figure BDA0000815298170000021
Ar1and Ar2The same or different, are respectively and independently selected from H, halogen and substituted or unsubstituted C4-C30Aryl ring radical of (2), substituted or unsubstituted C4-C30Heteroaryl ring radical, substituted or unsubstituted C4-C30Condensed ring aryl, substituted or unsubstituted C4-C30Fused heterocyclic aryl, substituted or unsubstituted alkyl, cycloalkyl, cyano, aromatic secondary amine, aliphatic secondary amine, substituted or unsubstituted carbazol-9-yl, aromatic and aliphatic substituted pyridyl, or benzimidazolyl substituted phenyl;
Ar1and Ar2Not simultaneously from H.
The substituent on the aromatic ring group, the heteroaromatic ring group, the condensed ring aryl group and the condensed heterocyclic aryl group is the aromatic ring group, the heteroaromatic ring group, the condensed ring aryl group or the condensed heterocyclic aryl group, substituted or unsubstituted alkyl, naphthenic base, secondary amino, cyano-group and halogen.
The substituted or unsubstituted aromatic hydrocarbon group is phenyl, o-tolyl, p-tolyl or tert-butylphenyl; the substituted or unsubstituted heterocyclic aromatic hydrocarbon group is furan, benzofuran, dibenzofuran, thiophene, benzothiophene, dibenzothiophene, carbazole, pyridine, pyrazine, 2.4-methyl-1.3.5 triazine or 4.6 diphenyl pyrimidine and the like; the substituted or unsubstituted condensed ring aromatic hydrocarbon group is naphthyl, phenanthryl, anthryl, pyrenyl,
Figure BDA0000815298170000023
A fluorenyl, triphenylene, or 9, 9-dimethyl-2-fluorenyl group; the substituted or unsubstituted fused heterocyclic aromatic hydrocarbon group is quinolineIsoquinoline, quinazoline; substituted or unsubstituted alkyl is trifluoromethyl or alkyl.
The formula (1) preferably has a specific structure shown by the following formulae (4) to (47):
Figure BDA0000815298170000022
Figure BDA0000815298170000031
Figure BDA0000815298170000041
the application of the phenazine derivative in an organic electroluminescent device.
The phenazine derivative is useful as an electron transport material.
An organic electroluminescent device comprises a substrate, and an anode layer, an organic light-emitting functional layer and a cathode layer which are sequentially formed on the substrate; the organic light-emitting functional layer comprises a hole transport layer, an organic light-emitting layer and an electron transport layer, and the electron transport material of the electron transport layer is the phenazine derivative as defined in any one of claims 1 to 5.
Compared with the prior art, the phenazine-containing derivative has the advantages that:
the condensed ring aromatic hydrocarbon derivative of the quinoxaline group belongs to a typical electron-deficient system, and has suitable HOMO and LUMO energy levels, so that the condensed ring aromatic hydrocarbon derivative has good electron accepting capacity. The condensed ring aromatic hydrocarbon system which is coplanar in a space structure has good electron transfer capability. Therefore, the benzacridine compound is an excellent electron transport material.
Experiments show that when the condensed ring aromatic hydrocarbon derivative of the quinoxaline group is used as an electron transmission material, compared with Bphen which is used as the electron transmission material, the driving voltage of a device is reduced, the working voltage of the device is effectively reduced, the lumen efficiency is improved, the power consumption of the device is reduced, and the condensed ring aromatic hydrocarbon derivative is an electron transmission material with good performance.
Drawings
FIG. 1 shows a nuclear magnetic spectrum of a compound represented by the formula (9) ((1HNMR)；
FIG. 2 is a nuclear magnetic spectrum of a compound represented by the formula (15) ((1HNMR)；
FIG. 3 is a nuclear magnetic spectrum of a compound represented by the formula (26) ((R))1HNMR)；
FIG. 4 is a nuclear magnetic spectrum of a compound represented by the formula (31) ((1HNMR)；
FIG. 5 is a nuclear magnetic spectrum of a compound represented by the formula (36) ((R))1HNMR)；
FIG. 6 is a nuclear magnetic spectrum of a compound represented by the formula (45) ((1HNMR)。
Detailed Description
Basic raw materials used in the present invention, for example, 4-bromoo-phenylenediamine, 4-bromoo-benzoquinone (4-bromocyclohexane-3, 5-diene-1, 2-dione), various brominated derivatives of anthracene, brominated derivatives of diphenylbenzofluoranthene, brominated derivatives of diphenylfluoranthene, various brominated derivatives of triphenylene, and the like
Figure BDA0000815298170000053
The bromo-derivative of (A) and various bromo-derivatives of pyrene can be purchased in various chemical raw material markets at home or can be synthesized by a common method in a laboratory.
The various bromides can be prepared into corresponding boric acid compounds by a common method.
A phenazine derivative having a structure represented by formula (1):
Figure BDA0000815298170000051
wherein: ar (Ar)1And Ar2The same or different, are respectively and independently selected from H, halogen and substituted or unsubstituted C4-C30Aryl ring radical of (2), substituted or unsubstituted C4-C30Heteroaryl ring radical, substituted or unsubstituted C4-C30Condensed ring aryl, substitutedSubstituted or unsubstituted C4-C30Fused heterocyclic aryl, substituted or unsubstituted alkyl, cycloalkyl, cyano, aromatic secondary amine, aliphatic secondary amine, substituted or unsubstituted carbazol-9-yl, aromatic and aliphatic substituted pyridyl, or benzimidazolyl substituted phenyl; ar (Ar)1And Ar2Not simultaneously from H.
Preferably, the formula (1) is a structure represented by formula (2) and formula (3):
Figure BDA0000815298170000052
Ar1and Ar2The same or different, are respectively and independently selected from H, halogen and substituted or unsubstituted C4-C30Aryl ring radical of (2), substituted or unsubstituted C4-C30Heteroaryl ring radical, substituted or unsubstituted C4-C30Condensed ring aryl, substituted or unsubstituted C4-C30Fused heterocyclic aryl, substituted or unsubstituted alkyl, cycloalkyl, cyano, aromatic secondary amine, aliphatic secondary amine, substituted or unsubstituted carbazol-9-yl, aromatic and aliphatic substituted pyridyl, or benzimidazolyl substituted phenyl;
Ar1and Ar2Not simultaneously from H.
The substituent on the aromatic ring group, the heteroaromatic ring group, the condensed ring aryl group and the condensed heterocyclic aryl group is the aromatic ring group, the heteroaromatic ring group, the condensed ring aryl group or the condensed heterocyclic aryl group, substituted or unsubstituted alkyl, naphthenic base, secondary amino, cyano-group and halogen.
The substituted or unsubstituted aromatic hydrocarbon group is phenyl, o-tolyl, p-tolyl or tert-butylphenyl; the substituted or unsubstituted heterocyclic aromatic hydrocarbon group is furan, benzofuran, dibenzofuran, thiophene, benzothiophene, dibenzothiophene, carbazole, pyridine, pyrazine, 2.4-methyl-1.3.5 triazine or 4.6 diphenyl pyrimidine and the like; the substituted or unsubstituted condensed ring aromatic hydrocarbon group is naphthyl, phenanthryl, anthryl, pyrenyl,
Figure BDA0000815298170000054
A fluorenyl, triphenylene, or 9, 9-dimethyl-2-fluorenyl group; the substituted or unsubstituted fused heterocyclic aromatic hydrocarbon group is quinoline, isoquinoline or quinazoline; substituted or unsubstituted alkyl is trifluoromethyl or alkyl.
The formula (1) preferably has a specific structure shown by the following formulae (4) to (47):
Figure BDA0000815298170000061
Figure BDA0000815298170000071
the application of the phenazine derivative in an organic electroluminescent device.
The phenazine derivative is useful as an electron transport material.
An organic electroluminescent device comprises a substrate, and an anode layer, an organic light-emitting functional layer and a cathode layer which are sequentially formed on the substrate; the organic light-emitting functional layer comprises a hole transport layer, an organic light-emitting layer and an electron transport layer, and the electron transport material of the electron transport layer is the phenazine derivative as defined in any one of claims 1 to 5.
Example 1 Synthesis of dibromophenazine
Figure BDA0000815298170000072
Adding 3.91 g (molecular weight 186, 0.021mol) of 4-bromo o-phenylenediamine, 3.91 g (molecular weight 186, 0.021mol) of 4-bromo o-benzoquinone and 40 ml of ethanol into a 250ml three-neck flask, dropwise adding 0.2 g of concentrated sulfuric acid (concentration 98%) within 3min under the stirring condition, reacting for 4 hours at 65 ℃, cooling to room temperature after the reaction is finished, filtering, washing with water, drying, separating by column chromatography, eluting with ethyl acetate/petroleum ether to obtain 5.82 g (molecular weight 336) of almost equal 2, 7-dibromo phenazine and 2, 8-dibromo phenazine, and the total yield is 82.4%.
Example 2
Synthesis of Compound represented by the formula (4)
Figure BDA0000815298170000081
A1000 ml three-neck flask is stirred by magnetic force and protected by nitrogen, and 6.72g (molecular weight 336, 0.02mol) of 2, 8-dibromophenazine, 7.4g (molecular weight 172, 0.043mol) of naphthalene-2-boric acid, 2.3g (molecular weight 1154, 0.002mol) of tetrakis (triphenylphosphine) palladium, 100ml of 2M sodium carbonate aqueous solution, 100ml of toluene and 100ml of ethanol are added. After argon displacement, reflux was carried out, the reaction was monitored by Thin Layer Chromatography (TLC), and after 3.5 hours TLC found that the starting bromide reacted completely, leaving only product sites. And (3) cooling, separating an organic layer, evaporating to dryness, performing column chromatography separation, and leaching with ethyl acetate/petroleum ether to obtain 8.1g of the compound shown in the formula (4), wherein the molecular weight is 432, and the yield is 93.8%.
Product MS (m/e): 432, elemental analysis (C)32H20N2): theoretical value C: 88.86%, H: 4.66%, N: 6.48 percent; found value C: 88.83%, H: 4.67%, N: 6.50 percent.
Example 3
Synthesis of Compound represented by the formula (5)
The procedure was as in example 2 except that naphthalene-2-boronic acid was changed to naphthalene-1-boronic acid, and the other reagents were not changed to give a compound represented by the formula (5).
Product MS (m/e): 432, elemental analysis (C)32H20N2): theoretical value C: 88.86%, H: 4.66%, N: 6.48 percent; found value C: 88.88%, H: 4.67%, N: 6.45 percent.
Example 4
Synthesis of Compound represented by the formula (6)
The procedure was the same as in example 2 except that 2, 8-dibromophenazine was changed to 2, 7-dibromophenazine, and the other reagents were not changed to give a compound represented by the formula (6).
Product MS (m/e): 432, elemental analysis (C)32H20N2): theoretical value C: 88.86%, H: 4.66%, N: 6.48 percent; found value C: 88.85%, H: 4.69%, N: 6.46 percent。
Example 5
Synthesis of Compound represented by the formula (7)
The procedure was the same as in example 2 except that 2, 8-dibromophenazine was changed to 2, 7-dibromophenazine, naphthalene-2-boronic acid was changed to naphthalene-1-boronic acid, and the other reagents were not changed to give a compound represented by formula (7).
Product MS (m/e): 432, elemental analysis (C)32H20N2): theoretical value C: 88.86%, H: 4.66%, N: 6.48 percent; found value C: 88.84%, H: 4.69%, N: 6.47 percent.
Example 6
Synthesis of Compound represented by the formula (8)
The procedure was as in example 2 except that the starting naphthalene-2-boronic acid was changed to p- (naphthalene-1-yl) phenylboronic acid and the other reagents were changed to give a compound represented by the formula (8).
Product MS (m/e): 584, elemental analysis (C)44H28N2): theoretical value C: 90.38%, H: 4.83%, N: 4.79 percent; found value C: 90.34%, H: 4.86%, N: 4.82 percent.
Example 7
Synthesis of Compound represented by the formula (9)
The procedure of synthesis was the same as in example 2 except that the starting material naphthalene-2-boronic acid was changed to p- (naphthalene-2-yl) phenylboronic acid and the other reagents were changed to give a compound represented by formula (9); nuclear magnetic spectrum of (1HNMR) is shown in fig. 1.
Product MS (m/e): 584, elemental analysis (C)44H28N2): theoretical value C: 90.38%, H: 4.83%, N: 4.79 percent; found value C: 90.37%, H: 4.82%, N: 4.81 percent; nuclear magnetic spectrum of (1HNMR) is shown in fig. 1.
Example 8
Synthesis of Compound represented by the formula (10)
The procedure was the same as in example 2 except that the starting material 2, 8-dibromophenazine was changed to 2, 7-dibromophenazine, naphthalene-2-boronic acid was changed to p- (naphthalene-2-yl) phenylboronic acid, and the other reagents were not changed to give a compound represented by formula (10).
Product MS (m/e): 584, elemental analysis (C)44H28N2): theoretical value C: 90.38%, H: 4.83%, N: 4.79 percent; found value C: 90.33%, H: 4.86%, N: 4.81 percent.
Example 9
Synthesis of Compound represented by the formula (11)
The procedure was the same as in example 2 except that the starting material 2, 8-dibromophenazine was changed to 2, 7-dibromophenazine, naphthalene-2-boronic acid was changed to p- (naphthalene-1-yl) phenylboronic acid, and the other reagents were not changed to give a compound represented by formula (11).
Product MS (m/e): 584, elemental analysis (C)44H28N2): theoretical value C: 90.38%, H: 4.83%, N: 4.79 percent; found value C: 90.37%, H: 4.86%, N: 4.77 percent.
Example 10
Synthesis of Compound represented by the formula (12)
The procedure was as in example 2 except that the starting naphthalene-2-boronic acid was changed to phenanthrene-9-boronic acid and the other reagents were changed to give the compound represented by formula (12).
Product MS (m/e): 532, elemental analysis (C)40H24N2): theoretical value C: 90.20%, H: 4.54%, N: 5.26 percent; found value C: 90.23%, H: 4.55%, N: 5.22 percent.
Example 11
Synthesis of Compound represented by the formula (13)
The synthesis procedure was the same as in example 2 except that the starting material 2, 8-dibromophenazine was changed to 2, 7-dibromophenazine, naphthalene-2-boronic acid was changed to phenanthrene-9-boronic acid, and the other reagents were unchanged to give the compound represented by formula (13).
Product MS (m/e): 532, elemental analysis (C)40H24N2): theoretical value C: 90.20%, H: 4.54%, N: 5.26 percent; found value C: 90.24%, H: 4.52%, N: 5.24 percent.
Example 12
Synthesis of Compound represented by the formula (14)
The procedure was as in example 2 except that the starting naphthalene-2-boronic acid was changed to p- (phenanthren-9-yl) phenylboronic acid and the other reagents were changed to give a compound represented by formula (14).
Product MS (m/e): 684 elemental analysis (C)52H32N2): theoretical value C: 91.20%, H: 4.71%, N: 4.09%; found value C: 91.23%, H: 4.72%, N: 4.05 percent.
Example 13
Synthesis of Compound represented by the formula (15)
The synthesis procedure was the same as in example 2 except that the starting material 2, 8-dibromophenazine was changed to 2, 7-dibromophenazine, naphthalene-2-boronic acid was changed to p- (phenanthrene-9-yl) phenylboronic acid, and the other reagents were unchanged to give the compound represented by formula (15).
Product MS (m/e): 684 elemental analysis (C)52H32N2): theoretical value C: 91.20%, H: 4.71%, N: 4.09%; found value C: 91.22%, H: 4.74%, N: 4.04 percent; nuclear magnetic spectrum of (1HNMR) is shown in fig. 2.
Example 14
Synthesis of Compound represented by the formula (16)
The procedure was the same as in example 2 except that the starting material naphthalene-2-boronic acid was changed to pyrene-1-boronic acid, and the other reagents were not changed to obtain a compound represented by formula (16).
Product MS (m/e): 580, elemental analysis (C)44H24N2): theoretical value C: 91.01%, H: 4.17%, N: 4.82%; found value C: 91.03%, H: 4.13%, N: 4.84 percent.
Example 15
Synthesis of Compound represented by the formula (17)
The synthesis procedure was the same as in example 2 except that the starting material 2, 8-dibromophenazine was changed to 2, 7-dibromophenazine, naphthalene-2-boronic acid was changed to pyrene-1-boronic acid, and the other reagents were unchanged to obtain the compound represented by formula (17).
Product MS (m/e): 580, elemental analysis (C)44H24N2): theoretical value C: 91.01%, H: 4.17%, N: 4.82%; found value C: 91.02%, H: 4.15%, N: 4.83 percent.
Example 16
Synthesis of Compound represented by the formula (18)
The procedure was the same as in example 2 except that the starting naphthalene-2-boronic acid was changed to p- (pyrene-1-yl) phenylboronic acid and the other reagents were changed to give a compound represented by formula (18).
Product MS (m/e): 732 elemental analysis (C)56H32N2): theoretical value C: 91.78%, H: 4.40%, N: 3.82 percent; found value C: 91.73%, H: 4.43%, N: 3.84 percent.
Example 17
Synthesis of Compound represented by the formula (19)
The synthesis procedure was the same as in example 2 except that the starting material 2, 8-dibromophenazine was changed to 2, 7-dibromophenazine, naphthalene-2-boronic acid was changed to p- (pyrene-1-yl) phenylboronic acid, and the other reagents were unchanged to give a compound represented by formula (19).
Product MS (m/e): 732 elemental analysis (C)56H32N2): theoretical value C: 91.78%, H: 4.40%, N: 3.82 percent; found value C: 91.74%, H: 4.41%, N: 3.85 percent.
Example 18
Synthesis of Compound represented by the formula (20)
The synthesis reaction is divided into two steps. The first step is the same as example 2, except that naphthalene-2-boronic acid is changed into p- (naphthalene-1-yl) phenylboronic acid, 2, 8-dibromophenazine and p- (naphthalene-1-yl) phenylboronic acid are fed in equimolar amount, other reagents and reaction conditions are not changed, and column chromatography separation is carried out after reaction to obtain monobromo product;
the second step was the same as example 2 except that the starting material 2, 8-dibromophenazine was changed to the monobromo product obtained in the first step herein, naphthalene-2-boronic acid was changed to pyrene-1-boronic acid, and the monobromo product obtained in the first step was charged in equimolar amounts with pyrene-1-boronic acid, and the other reagents and reaction conditions were not changed, and after the reaction, column chromatography was performed to obtain the compound represented by formula (20).
Product MS (m/e): 582, elemental analysis (C)44H26N2): theoretical value C: 90.69%, H: 4.50%, N: 4.81 percent; found value C: 90.64%, H: 4.52%, N: 4.84 percent.
Example 19
Synthesis of Compound represented by the formula (21)
The synthesis reaction is divided into two steps.
The first step is the same as example 2, except that the raw material 2, 8-dibromophenazine is changed into 2, 7-dibromophenazine, naphthalene-2-boric acid is changed into p- (naphthalene-1-yl) phenylboronic acid, 2, 7-dibromophenazine and p- (naphthalene-1-yl) phenylboronic acid are fed in equimolar amount, other reagents and reaction conditions are not changed, and the monobromo product is obtained by column chromatography separation after the reaction;
the second step was the same as example 2 except that 2, 8-dibromophenazine was changed to the monobromo product obtained in the first step herein, naphthalene-2-boronic acid was changed to pyrene-1-boronic acid, and the monobromo product obtained in the first step was charged in equimolar amounts with pyrene-1-boronic acid, other reagents and reaction conditions were not changed, and after the reaction, column chromatography was performed to obtain the compound represented by formula (21).
Product MS (m/e): 582, elemental analysis (C)44H26N2): theoretical value C: 90.69%, H: 4.50%, N: 4.81 percent; found value C: 90.65%, H: 4.53%, N: 4.82 percent.
Example 20
Synthesis of Compound represented by the formula (22)
The procedure was as in example 2 except that the starting naphthalene-2-boronic acid was changed to 9-phenylanthracene-10-boronic acid, and the other reagents were changed to give a compound represented by the formula (22).
Product MS (m/e): 684 elemental analysis (C)52H32N2): theoretical value C: 91.20%, H: 4.71%, N: 4.09%; found value C: 91.23%, H: 4.73%, N: 4.04 percent.
Example 21
Synthesis of Compound represented by the formula (23)
The procedure was the same as in example 2 except that 2, 8-dibromophenazine was changed to 2, 7-dibromophenazine, naphthalene-2-boronic acid was changed to 9-phenylanthracene-10-boronic acid, and the other reagents were changed to give a compound represented by formula (23).
Product MS (m/e): 684 elemental analysis (C)52H32N2): theoretical value C: 91.20%, H: 4.71%, N: 4.09%; found value C: 91.22%, H: 4.72%, N: 4.06 percent.
Example 22
Synthesis of Compound represented by the formula (24)
The synthesis reaction is divided into two steps.
The first step is the same as the example 2, except that the raw material naphthalene-2-boric acid is changed into p- (naphthalene-1-yl) phenylboronic acid, 2, 8-dibromophenazine and p- (naphthalene-1-yl) phenylboronic acid are fed in equimolar amount, other reagents and reaction conditions are not changed, and the monobromo product is obtained after column chromatography separation after the reaction;
the second procedure was the same as in example 2 except that 2, 8-dibromophenazine was changed to monobromo product obtained in the first step herein, naphthalene-2-boronic acid was changed to 9-phenylanthracene-10-boronic acid, and monobromo product obtained in the first step was charged in equimolar amounts with 9-phenylanthracene-10-boronic acid, other reagents and reaction conditions were not changed, and the compound represented by formula (24) was obtained by column chromatography after the reaction.
Product MS (m/e): 634, elemental analysis (C)48H30N2): theoretical value C: 90.82%, H: 4.76%, N: 4.41 percent; found value C: 90.84%, H: 4.72%, N: 4.44 percent.
Example 23
Synthesis of Compound represented by the formula (25)
The synthesis reaction is divided into two steps.
The first step is the same as example 2, except that the raw material 2, 8-dibromophenazine is changed into 2, 7-dibromophenazine, naphthalene-2-boric acid is changed into p- (naphthalene-1-yl) phenylboronic acid, 2, 7-dibromophenazine and p- (naphthalene-1-yl) phenylboronic acid are fed in equimolar amount, other reagents and reaction conditions are not changed, and the monobromo product is obtained by column chromatography separation after the reaction;
the second procedure was the same as in example 2 except that 2, 8-dibromophenazine was changed to monobromo product obtained in the first step herein, naphthalene-2-boronic acid was changed to 9-phenylanthracene-10-boronic acid, and monobromo product obtained in the first step was charged in equimolar amounts with 9-phenylanthracene-10-boronic acid, other reagents and reaction conditions were not changed, and the compound represented by formula (25) was obtained by column chromatography after the reaction.
Product MS (m/e): 634, elemental analysis (C)48H30N2): theoretical value C: 90.82%, H: 4.76%, N: 4.41 percent(ii) a Found value C: 90.83%, H: 4.74%, N: 4.43 percent.
Example 24
Synthesis of Compound represented by the formula (26)
The procedure of synthesis was the same as in example 2 except that the starting naphthalene-2-boronic acid was changed to 7, 10-diphenylfluoranthene-3-boronic acid, and the other reagents were not changed to give a compound represented by formula (26).
Product MS (m/e): 884 elemental analysis (C)68H40N2): theoretical value C: 92.28%, H: 4.56%, N: 3.17 percent; found value C: 92.32%, H: 4.54%, N: 3.14 percent; nuclear magnetic spectrum of (1HNMR) is shown in fig. 3.
Example 25
Synthesis of Compound represented by the formula (27)
The procedure of synthesis was the same as in example 2 except that the starting material 2, 8-dibromophenazine was changed to 2, 7-dibromophenazine, naphthalene-2-boronic acid was changed to 7, 10-diphenylfluoranthene-3-boronic acid, and the other reagents were not changed to give a compound represented by formula (27).
Product MS (m/e): 884 elemental analysis (C)68H40N2): theoretical value C: 92.28%, H: 4.56%, N: 3.17 percent; found value C: 92.30%, H: 4.54%, N: 3.16 percent.
Example 26
Synthesis of Compound represented by the formula (28)
The synthesis reaction is divided into two steps.
The first step is the same as the example 2, except that the raw material 2, 8-dibromophenazine is changed into 2, 7-dibromophenazine, naphthalene-2-boric acid is changed into 2-phenylpyridine-5-boric acid, the 2, 7-dibromophenazine and the 2-phenylpyridine-5-boric acid are fed in equimolar amount, other reagents and reaction conditions are not changed, and the monobromo product is obtained after column chromatography separation after the reaction;
the second procedure was the same as in example 2 except that 2, 8-dibromophenazine was changed to the monobromo product obtained in the first procedure herein, naphthalene-2-boronic acid was changed to p- (9-phenylanthracen-10-yl) phenylboronic acid, and the monobromo product obtained in the first procedure was equimolar dosed with p- (9-phenylanthracen-10-yl) phenylboronic acid, the other reagents and reaction conditions were unchanged, and after the reaction, column chromatography was performed to obtain the compound represented by formula (28).
Product MS (m/e): 661 elemental analysis (C)49H31N3): theoretical value C: 88.93%, H: 4.72%, N: 6.35 percent; found value C: 88.91%, H: 4.76%, N: 6.33 percent.
Example 27
Synthesis of Compound represented by the formula (29)
The synthesis reaction is divided into two steps.
The first step is the same as example 2, except that the raw material naphthalene-2-boronic acid is changed into 2-phenylpyridine-5-boronic acid, the 2, 8-dibromophenazine and the 2-phenylpyridine-5-boronic acid are fed in an equimolar way, other reagents and reaction conditions are not changed, and the monobromo product is obtained after column chromatography separation after the reaction;
the second procedure was the same as in example 2 except that 2, 8-dibromophenazine was changed to the monobromo product obtained in the first procedure herein, naphthalene-2-boronic acid was changed to p- (9-phenylanthracen-10-yl) phenylboronic acid, and the monobromo product obtained in the first procedure was equimolar dosed with p- (9-phenylanthracen-10-yl) phenylboronic acid, the other reagents and reaction conditions were unchanged, and after the reaction, column chromatography was performed to obtain the compound represented by formula (29).
Product MS (m/e): 661 elemental analysis (C)49H31N3): theoretical value C: 88.93%, H: 4.72%, N: 6.35 percent; found value C: 88.95%, H: 4.73%, N: 6.32 percent.
Example 28
Synthesis of Compound represented by the formula (30)
The synthesis reaction is divided into two steps.
The first step is the same as example 2, except that the raw material naphthalene-2-boronic acid is changed into 2-phenylpyridine-5-boronic acid, the 2, 8-dibromophenazine and the 2-phenylpyridine-5-boronic acid are fed in an equimolar way, other reagents and reaction conditions are not changed, and the monobromo product is obtained after column chromatography separation after the reaction;
the second step was the same as example 2 except that 2, 8-dibromophenazine was changed to the monobromo product obtained in the first step herein, naphthalene-2-boronic acid was changed to pyrene-1-boronic acid, and the monobromo product obtained in the first step was charged in equimolar amounts with pyrene-1-boronic acid, other reagents and reaction conditions were not changed, and after the reaction, column chromatography was performed to obtain the compound represented by formula (30).
Product MS (m/e): 533, elemental analysis (C)39H23N3): theoretical value C: 87.78%, H: 4.34%, N: 7.87 percent; found value C: 87.81%, H: 4.35%, N: 7.84 percent.
Example 29
Synthesis of Compound represented by the formula (31)
The synthesis reaction is divided into two steps.
The first step is the same as the example 2, except that the raw material 2, 8-dibromophenazine is changed into 2, 7-dibromophenazine, naphthalene-2-boric acid is changed into 2-phenylpyridine-5-boric acid, the 2, 7-dibromophenazine and the 2-phenylpyridine-5-boric acid are fed in equimolar amount, other reagents and reaction conditions are not changed, and the monobromo product is obtained after column chromatography separation after the reaction;
the second step was the same as example 2 except that 2, 8-dibromophenazine was changed to the monobromo product obtained in the first step herein, naphthalene-2-boronic acid was changed to pyrene-1-boronic acid, and the monobromo product obtained in the first step was charged in equimolar amounts with pyrene-1-boronic acid, other reagents and reaction conditions were not changed, and after the reaction, column chromatography was performed to obtain the compound represented by formula (31).
Product MS (m/e): 533, elemental analysis (C)39H23N3): theoretical value C: 87.78%, H: 4.34%, N: 7.87 percent; found value C: 87.82%, H: 4.33%, N: 7.85 percent; nuclear magnetic spectrum of (1HNMR) is shown in fig. 4.
Example 30
Synthesis of Compound represented by the formula (32)
The synthesis reaction is divided into two steps.
The first step is the same as example 2, except that the raw material naphthalene-2-boronic acid is changed into 2-phenylpyridine-5-boronic acid, the 2, 8-dibromophenazine and the 2-phenylpyridine-5-boronic acid are fed in an equimolar way, other reagents and reaction conditions are not changed, and the monobromo product is obtained after column chromatography separation after the reaction;
the second procedure was the same as in example 2 except that 2, 8-dibromophenazine was changed to the monobromo product obtained in the first procedure herein, naphthalene-2-boronic acid was changed to p- (naphthalen-1-yl) phenylboronic acid, and the monobromo product obtained in the first procedure was charged in equimolar amounts with p- (naphthalen-1-yl) phenylboronic acid, the other reagents and reaction conditions were unchanged, and the compound represented by formula (32) was obtained by column chromatography after the reaction.
Product MS (m/e): 535, elemental analysis (C)39H25N3): theoretical value C: 87.45%, H: 4.70%, N: 7.84 percent; found value C: 87.43%, H: 4.75%, N: 7.82 percent.
Example 31
Synthesis of Compound represented by the formula (33)
The synthesis reaction is divided into two steps.
The first step is the same as the example 2, except that the raw material 2, 8-dibromophenazine is changed into 2, 7-dibromophenazine, naphthalene-2-boric acid is changed into 2-phenylpyridine-5-boric acid, the 2, 7-dibromophenazine and the 2-phenylpyridine-5-boric acid are fed in equimolar amount, other reagents and reaction conditions are not changed, and the monobromo product is obtained after column chromatography separation after the reaction;
the second procedure was the same as in example 2 except that 2, 8-dibromophenazine was changed to the monobromo product obtained in the first procedure herein, naphthalene-2-boronic acid was changed to p- (naphthalen-1-yl) phenylboronic acid, and the monobromo product obtained in the first procedure was charged in equimolar amounts with p- (naphthalen-1-yl) phenylboronic acid, the other reagents and reaction conditions were unchanged, and the compound represented by formula (33) was obtained by column chromatography after the reaction.
Product MS (m/e): 535, elemental analysis (C)39H25N3): theoretical value C: 87.45%, H: 4.70%, N: 7.84 percent; found value C: 87.41%, H: 4.73%, N: 7.86 percent.
Example 32
Synthesis of Compound represented by the formula (34)
The synthesis reaction is divided into two steps.
The first step is the same as example 2, except that the raw material naphthalene-2-boronic acid is changed into 2-phenylpyridine-5-boronic acid, the 2, 8-dibromophenazine and the 2-phenylpyridine-5-boronic acid are fed in an equimolar way, other reagents and reaction conditions are not changed, and the monobromo product is obtained after column chromatography separation after the reaction;
the second step is the same as example 2 except that 2, 8-dibromophenazine is changed to the monobromo product obtained in the first step, naphthalene-2-boronic acid is changed to phenanthrene-9-boronic acid, the monobromo product obtained in the first step and phenanthrene-9-boronic acid are charged in equimolar amounts, other reagents and reaction conditions are not changed, and after the reaction, column chromatography is performed to obtain the compound represented by formula (34).
Product MS (m/e): 509, elemental analysis (C)37H23N3): theoretical value C: 87.21%, H: 4.55%, N: 8.25 percent; found value C: 87.23%, H: 4.54%, N: 8.23 percent.
Example 33
Synthesis of Compound represented by the formula (35)
The synthesis reaction is divided into two steps.
The first step is the same as the example 2, except that the raw material 2, 8-dibromophenazine is changed into 2, 7-dibromophenazine, naphthalene-2-boric acid is changed into 2-phenylpyridine-5-boric acid, the 2, 7-dibromophenazine and the 2-phenylpyridine-5-boric acid are fed in equimolar amount, other reagents and reaction conditions are not changed, and the monobromo product is obtained after column chromatography separation after the reaction;
the second step is the same as example 2 except that 2, 8-dibromophenazine is changed to the monobromo product obtained in the first step, naphthalene-2-boronic acid is changed to phenanthrene-9-boronic acid, the monobromo product obtained in the first step and phenanthrene-9-boronic acid are charged in equimolar amounts, other reagents and reaction conditions are not changed, and after the reaction, column chromatography is performed to separate the compound shown in formula (35).
Product MS (m/e): 509, elemental analysis (C)37H23N3): theoretical value C: 87.21%, H: 4.55%, N: 8.25 percent; found value C: 87.22%, H: 4.51%, N: 8.27 percent.
Example 34
Synthesis of Compound represented by the formula (36)
The synthesis reaction is divided into two steps.
The first step is the same as example 2, except that the raw material 2, 8-dibromophenazine is changed into 2, 7-dibromophenazine, naphthalene-2-boric acid is changed into 4- (2-phenyl-1H-benzo [ d ] imidazol-1-yl) phenylboronic acid, and the 2, 7-dibromophenazine and the 4- (2-phenyl-1H-benzo [ d ] imidazol-1-yl) phenylboronic acid are fed in equimolar amount, other reagents and reaction conditions are not changed, and column chromatography is carried out after the reaction to obtain a monobromo product;
the second step is the same as example 2 except that 2, 8-dibromophenazine is changed to the monobromo product obtained in the first step, naphthalene-2-boronic acid is changed to phenanthrene-9-boronic acid, the monobromo product obtained in the first step and phenanthrene-9-boronic acid are charged in equimolar amounts, other reagents and reaction conditions are not changed, and after the reaction, column chromatography is performed to obtain the compound represented by formula (36).
Product MS (m/e): 624, elemental analysis (C)45H28N4): theoretical value C: 86.51%, H: 4.52%, N: 8.97 percent; found value C: 86.53%, H: 4.54%, N: 8.93 percent; nuclear magnetic spectrum of (1HNMR) is shown in fig. 5.
Example 35
Synthesis of Compound represented by the formula (37)
The synthesis reaction is divided into two steps.
The first step is the same as example 2, except that the raw material naphthalene-2-boronic acid is changed into 4- (2-phenyl-1H-benzo [ d ] imidazol-1-yl) phenylboronic acid, 2, 8-dibromophenazine and 4- (2-phenyl-1H-benzo [ d ] imidazol-1-yl) phenylboronic acid are fed in equimolar amount, other reagents and reaction conditions are not changed, and column chromatography is carried out after the reaction to obtain monobromo product;
the second step is the same as example 2 except that 2, 8-dibromophenazine is changed to the monobromo product obtained in the first step, naphthalene-2-boronic acid is changed to phenanthrene-9-boronic acid, the monobromo product obtained in the first step and phenanthrene-9-boronic acid are charged in equimolar amounts, other reagents and reaction conditions are not changed, and after the reaction, column chromatography is performed to obtain the compound represented by formula (37).
Product MS (m/e): 624, elemental analysis (C)45H28N4): theoretical value C: 86.51%, H: 4.52%, N: 8.97 percent; found value C: 86.54%, H: 4.52%, N: 8.94 percent.
Example 36
Synthesis of Compound represented by the formula (38)
The synthesis reaction is divided into two steps.
The first step is the same as example 2, except that the raw material naphthalene-2-boronic acid is changed into 4- (2-phenyl-1H-benzo [ d ] imidazol-1-yl) phenylboronic acid, 2, 8-dibromophenazine and 4- (2-phenyl-1H-benzo [ d ] imidazol-1-yl) phenylboronic acid are fed in equimolar amount, other reagents and reaction conditions are not changed, and column chromatography is carried out after the reaction to obtain monobromo product;
the second procedure was the same as in example 2 except that 2, 8-dibromophenazine was changed to the monobromo product obtained in the first procedure herein, naphthalene-2-boronic acid was changed to p- (naphthalen-1-yl) phenylboronic acid, and the monobromo product obtained in the first procedure was charged in equimolar amounts with p- (naphthalen-1-yl) phenylboronic acid, the other reagents and reaction conditions were unchanged, and the compound represented by formula (38) was obtained by column chromatography after the reaction.
Product MS (m/e): 650, elemental analysis (C)47H30N4): theoretical value C: 86.74%, H: 4.65%, N: 8.61 percent; found value C: 86.72%, H: 4.64%, N: 8.64 percent.
Example 37
Synthesis of Compound represented by the formula (39)
The synthesis reaction is divided into two steps.
The first step is the same as example 2, except that the raw material 2, 8-dibromophenazine is changed into 2, 7-dibromophenazine, naphthalene-2-boric acid is changed into 4- (2-phenyl-1H-benzo [ d ] imidazol-1-yl) phenylboronic acid, and the 2, 7-dibromophenazine and the 4- (2-phenyl-1H-benzo [ d ] imidazol-1-yl) phenylboronic acid are fed in equimolar amount, other reagents and reaction conditions are not changed, and column chromatography is carried out after the reaction to obtain a monobromo product;
the second procedure was the same as in example 2 except that 2, 8-dibromophenazine was changed to the monobromo product obtained in the first procedure herein, naphthalene-2-boronic acid was changed to p- (naphthalen-1-yl) phenylboronic acid, and the monobromo product obtained in the first procedure was charged in equimolar amounts with p- (naphthalen-1-yl) phenylboronic acid, the other reagents and reaction conditions were unchanged, and the compound represented by formula (39) was obtained by column chromatography after the reaction.
Product MS (m/e): 650, elemental analysis (C)47H30N4): theoretical value C: 86.74%, H: 4.65%, N: 8.61 percent; found value C: 86.76%, H: 4.61%, N: 8.63 percent.
Example 38
Synthesis of Compound represented by the formula (40)
The synthesis reaction is divided into two steps.
The first step is the same as example 2, except that the raw material naphthalene-2-boronic acid is changed into 4- (2-phenyl-1H-benzo [ d ] imidazol-1-yl) phenylboronic acid, 2, 8-dibromophenazine and 4- (2-phenyl-1H-benzo [ d ] imidazol-1-yl) phenylboronic acid are fed in equimolar amount, other reagents and reaction conditions are not changed, and column chromatography is carried out after the reaction to obtain monobromo product;
the second step was the same as example 2 except that 2, 8-dibromophenazine was changed to the monobromo product obtained in the first step herein, naphthalene-2-boronic acid was changed to pyrene-1-boronic acid, and the monobromo product obtained in the first step was charged in equimolar amounts with pyrene-1-boronic acid, other reagents and reaction conditions were not changed, and after the reaction, column chromatography was performed to obtain the compound represented by formula (40).
Product MS (m/e): 648 elemental analysis (C)47H28N4): theoretical value C: 87.01%, H: 4.35%, N: 8.64 percent; found value C: 87.04%, H: 4.34%, N: 8.62 percent.
Example 39
Synthesis of Compound represented by the formula (41)
The synthesis reaction is divided into two steps.
The first step is the same as example 2, except that the raw material 2, 8-dibromophenazine is changed into 2, 7-dibromophenazine, naphthalene-2-boric acid is changed into 4- (2-phenyl-1H-benzo [ d ] imidazol-1-yl) phenylboronic acid, and the 2, 7-dibromophenazine and the 4- (2-phenyl-1H-benzo [ d ] imidazol-1-yl) phenylboronic acid are fed in equimolar amount, other reagents and reaction conditions are not changed, and column chromatography is carried out after the reaction to obtain a monobromo product;
the second step was the same as example 2 except that 2, 8-dibromophenazine was changed to the monobromo product obtained in the first step herein, naphthalene-2-boronic acid was changed to pyrene-1-boronic acid, and the monobromo product obtained in the first step was charged in equimolar amounts with pyrene-1-boronic acid, other reagents and reaction conditions were not changed, and after the reaction, column chromatography was performed to obtain the compound represented by formula (41).
Product MS (m/e): 648 elemental analysis (C)47H28N4): theoretical value C: 87.01%, H: 4.35%, N: 8.64 percent; found value C: 87.03%, H: 4.36%, N: 8.61 percent.
Example 40
Synthesis of Compound represented by the formula (42)
The synthesis reaction is divided into two steps.
The first step is the same as example 2, except that the raw material naphthalene-2-boronic acid is changed into 4- (2-phenyl-1H-benzo [ d ] imidazol-1-yl) phenylboronic acid, 2, 8-dibromophenazine and 4- (2-phenyl-1H-benzo [ d ] imidazol-1-yl) phenylboronic acid are fed in equimolar amount, other reagents and reaction conditions are not changed, and column chromatography is carried out after the reaction to obtain monobromo product;
the second procedure was the same as in example 2 except that 2, 8-dibromophenazine was changed to monobromo product obtained in the first step herein, naphthalene-2-boronic acid was changed to triphenylene-2-boronic acid, and the monobromo product obtained in the first step was charged in equimolar amounts with triphenylene-2-boronic acid, other reagents and reaction conditions were not changed, and after the reaction, column chromatography was carried out to obtain a compound represented by formula (42).
Product MS (m/e): 674, elemental analysis (C)49H30N4): theoretical value C: 87.22%, H: 4.48%, N: 8.30 percent; found value C: 87.24%, H: 4.43%, N: 8.33 percent.
EXAMPLE 41
Synthesis of Compound represented by the formula (43)
The synthesis reaction is divided into two steps.
The first step is the same as example 2, except that the raw material 2, 8-dibromophenazine is changed into 2, 7-dibromophenazine, naphthalene-2-boric acid is changed into 4- (2-phenyl-1H-benzo [ d ] imidazol-1-yl) phenylboronic acid, and the 2, 7-dibromophenazine and the 4- (2-phenyl-1H-benzo [ d ] imidazol-1-yl) phenylboronic acid are fed in equimolar amount, other reagents and reaction conditions are not changed, and column chromatography is carried out after the reaction to obtain a monobromo product;
the second procedure was the same as in example 2 except that 2, 8-dibromophenazine was changed to monobromo product obtained in the first step herein, naphthalene-2-boronic acid was changed to triphenylene-2-boronic acid, and the monobromo product obtained in the first step was charged in equimolar amounts with triphenylene-2-boronic acid, other reagents and reaction conditions were not changed, and after the reaction, column chromatography was carried out to obtain a compound represented by formula (43).
Product MS (m/e): 674, elemental analysis (C)49H30N4): theoretical value C: 87.22%, H: 4.48%, N: 8.30 percent; found value C: 87.23%, H: 4.45%, N: 8.32 percent.
Example 42
Synthesis of Compound represented by the formula (44)
The synthesis reaction is divided into two steps.
The first step is the same as example 2, except that the raw material naphthalene-2-boronic acid is changed into 2-phenylpyridine-5-boronic acid, the 2, 8-dibromophenazine and the 2-phenylpyridine-5-boronic acid are fed in an equimolar way, other reagents and reaction conditions are not changed, and the monobromo product is obtained after column chromatography separation after the reaction;
the second procedure was the same as in example 2 except that 2, 8-dibromophenazine was changed to monobromo product obtained in the first step herein, naphthalene-2-boronic acid was changed to triphenylene-2-boronic acid, and the monobromo product obtained in the first step was charged in equimolar amounts with triphenylene-2-boronic acid, other reagents and reaction conditions were not changed, and after the reaction, column chromatography was carried out to obtain a compound represented by formula (44).
Product MS (m/e): 559, elemental analysis (C)41H25N3): theoretical value C: 87.99%, H: 4.50%, N: 7.51 percent; found value C: 87.94%, H: 4.52%, N: 7.54 percent.
Example 43
Synthesis of Compound represented by the formula (45)
The synthesis reaction is divided into two steps.
The first step is the same as the example 2, except that the raw material 2, 8-dibromophenazine is changed into 2, 7-dibromophenazine, naphthalene-2-boric acid is changed into 2-phenylpyridine-5-boric acid, the 2, 7-dibromophenazine and the 2-phenylpyridine-5-boric acid are fed in equimolar amount, other reagents and reaction conditions are not changed, and the monobromo product is obtained after column chromatography separation after the reaction;
the second procedure was the same as in example 2 except that 2, 8-dibromophenazine was changed to monobromo product obtained in the first step herein, naphthalene-2-boronic acid was changed to triphenylene-2-boronic acid, and monobromo product obtained in the first step was charged in equimolar amounts to triphenylene-2-boronic acid, other reagents and reaction conditions were not changed, and after the reaction, column chromatography was performed to obtain a compound represented by formula (45).
Product MS (m/e): 559, elemental analysis (C)41H25N3): theoretical value C: 87.99%, H: 4.50%, N: 7.51 percent; found value C: 87.96%, H: 4.52%, N: 7.52 percent; nuclear magnetic spectrum of (1HNMR) is shown in fig. 1.
Example 44
Synthesis of Compound represented by the formula (46)
The procedure was as in example 2 except that the starting naphthalene-2-boronic acid was changed to triphenylene-2-boronic acid, and the other reagents were not changed to give a compound represented by the formula (46).
Product MS (m/e): 632, elemental analysis (C)48H28N2): theoretical value C: 91.11%, H: 4.46%, N: 4.43 percent; found value C: 91.14%, H: 4.42%, N: 4.44 percent.
Example 45
Synthesis of Compound represented by the formula (47)
The procedure was the same as in example 2 except that 2, 8-dibromophenazine was used as the starting material, 2, 7-dibromophenazine was used, naphthalene-2-boronic acid was used as the starting material, triphenylene-2-boronic acid was used as the starting material, and the other reagents were not used to obtain a compound represented by formula (47).
Product MS (m/e): 632, elemental analysis (C)48H28N2): theoretical value C: 91.11%, H: 4.46%, N: 4.43 percent; found value C: 91.12%, H: 4.43%, N: 4.45 percent.
The following are examples of the use of the compounds of the invention:
example 46
To facilitate comparison of the transport properties of these electron transport materials, the present inventors designed a simple electroluminescent device using EM1 as the emissive material (EM1 is the host material and not the emissive material in order not to pursue high efficiency but to verify the possibility of these materials being practical) and using the high efficiency electron transport material Bphen as the comparative material. The structures of EM1 and Bphen are:
Figure BDA0000815298170000201
the structure of the organic electroluminescent device in the embodiment of the invention is as follows:
substrate/anode/Hole Transport Layer (HTL)/organic light Emitting Layer (EL)/Electron Transport Layer (ETL)/cathode.
The substrate may be a substrate used in a conventional organic light emitting device, for example: glass or plastic. In the invention, the glass substrate and the ITO are used as anode materials in the manufacture of the organic electroluminescent device.
Various triarylamine-based materials may be used for the hole transport layer. The hole transport material selected for use in the fabrication of the organic electroluminescent device of the present invention is NPB. The NPB structure is:
Figure BDA0000815298170000202
the cathode can adopt a metal and a mixture structure thereof, such as Mg: ag. Ca: ag, etc., or an electron injection layer/metal layer structure, such as LiF/Al, Li2O/Al and the like. The cathode material selected in the preparation of the organic electroluminescent device is LiF/Al.
The compound in this embodiment is used as an electron transport material in an organic electroluminescent device, and the EML is used as a light emitting layer material, so that a plurality of organic electroluminescent devices are prepared, and the structure of each organic electroluminescent device is as follows: ITO/NPB (40nm)/EM1(30nm)/ETL material (20nm)/LiF (0.5nm)/Al (150 nm);
in one comparative organic electroluminescent device, Bphen was used as the electron transport material, and the materials of the present invention were used for the remaining organic electroluminescent devices.
The preparation process of the organic electroluminescent device in the embodiment is as follows:
the glass plate coated with the ITO transparent conductive layer was sonicated in a commercial detergent, rinsed in deionized water, washed in acetone: ultrasonically removing oil in an ethanol mixed solvent, baking in a clean environment until the water is completely removed, cleaning by using ultraviolet light and ozone, and bombarding the surface by using low-energy cationic beams;
placing the glass substrate with the anode in a vacuum chamber, and vacuumizing to 1 × 10-5～9×10-3Pa, on the anode layer filmPerforming vacuum vapor deposition on NPB as a hole transport layer, wherein the vapor deposition rate is 0.1nm/s, and the vapor deposition film thickness is 40 nm;
vacuum evaporating EM1 on the hole transport layer to serve as a light emitting layer of the device, wherein the evaporation rate is 0.1nm/s, and the total film thickness of the evaporation is 30 nm;
vacuum evaporating a compound represented by a layer (4), a formula (6), a formula (12), a formula (13), a formula (16), a formula (22), a formula (26), a formula (34), a formula (36), a formula (46) or a formula (47) on the luminescent layer to be used as an electron transport layer material of the device, using Bphen as a contrast material of the electron transport layer material of the device, wherein the evaporation rate is 0.1nm/s, and the total thickness of the evaporated film is 20 nm;
LiF with the thickness of 0.5nm is vacuum-evaporated on the Electron Transport Layer (ETL) to be used as an electron injection layer, and an Al layer with the thickness of 150nm is used as a cathode of the device.
The organic electroluminescent device properties are given in the following table:
compound numbering Required luminance cd/m2 Voltage V Current efficiency cd/A
Bphen 1000.00 6.2 6.1
Formula (4) 1000.00 5.7 6.8
Formula (6) 1000.00 5.7 6.9
Formula (12) 1000.00 5.6 6.8
Formula (13) 1000.00 5.5 7.1
Formula (16) 1000.00 5.6 7.2
Formula (22) 1000.00 5.6 7.1
Formula (26) 1000.00 5.7 7.1
Formula (34) 1000.00 5.6 7.3
Formula (36) 1000.00 5.7 7.2
Formula (46) 1000.00 5.6 7.3
Formula (47) 1000.00 5.7 7.1
The results show that the novel organic material is used for the organic electroluminescent device, can effectively reduce the working voltage of the device and improve the current efficiency, and is an electron transport material with good performance.
Although the invention has been described in connection with the embodiments, the invention is not limited to the embodiments described above, and it should be understood that various modifications and improvements can be made by those skilled in the art within the spirit of the invention, and the scope of the invention is outlined by the appended claims.

Claims (5)

1. A phenazine derivative having a structure represented by formula (2) and formula (3):
Figure FDA0002961919120000011
wherein: ar (Ar)1And Ar2Same or different, each is independently selected from substituted or unsubstituted C4-C30A fused ring aryl group;
the substituted or unsubstituted condensed ring aryl is naphthyl, phenanthryl, anthryl, pyrenyl, chrysene -yl, fluorenyl, triphenylene or 9, 9-dimethyl-2-fluorenyl.
2. A phenazine derivative having a structure represented by formula (2) and formula (3):
Figure FDA0002961919120000012
wherein: ar (Ar)1And Ar2Identical or different, each independently selected from benzimidazolyl-substituted phenyl groups.
3. A phenazine derivative having a specific structure represented by the following formulae (4) to (47):
Figure FDA0002961919120000013
Figure FDA0002961919120000021
Figure FDA0002961919120000031
4. use of a phenazine derivative according to any one of claims 1 to 3 as an electron transport material in an organic electroluminescent device.
5. An organic electroluminescent device comprises a substrate, and an anode layer, an organic light-emitting functional layer and a cathode layer which are sequentially formed on the substrate; the organic light-emitting functional layer comprises a hole transport layer, an organic light-emitting layer and an electron transport layer, and is characterized in that:
the electron transport material of the electron transport layer is the phenazine derivative according to any one of claims 1 to 3.
CN201510640793.8A 2015-09-30 2015-09-30 Phenazine derivative and application thereof in organic electroluminescent device Active CN106554322B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510640793.8A CN106554322B (en) 2015-09-30 2015-09-30 Phenazine derivative and application thereof in organic electroluminescent device

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510640793.8A CN106554322B (en) 2015-09-30 2015-09-30 Phenazine derivative and application thereof in organic electroluminescent device

Publications (2)

Publication Number Publication Date
CN106554322A CN106554322A (en) 2017-04-05
CN106554322B true CN106554322B (en) 2021-05-04

Family

ID=58417767

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510640793.8A Active CN106554322B (en) 2015-09-30 2015-09-30 Phenazine derivative and application thereof in organic electroluminescent device

Country Status (1)

Country Link
CN (1) CN106554322B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102066794B1 (en) * 2017-06-30 2020-01-15 주식회사 엘지화학 Compound and organic light emitting device comprising the same
CN110526874A (en) * 2019-08-28 2019-12-03 武汉华星光电半导体显示技术有限公司 Fluorenes and phenazene derivative and preparation method thereof and OLED device
CN111072578A (en) * 2019-11-25 2020-04-28 武汉华星光电半导体显示技术有限公司 P-type dopant and organic light emitting diode
CN113801102A (en) * 2021-10-11 2021-12-17 上海交通大学 Phenazinyl-based compound and preparation method and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998617A (en) * 1997-04-02 1999-12-07 Gentex Corporation Electrochromic compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101612903B1 (en) * 2013-04-09 2016-04-19 희성소재 (주) Phenazine-based compound and organic light emitting device comprising the same
KR102268119B1 (en) * 2013-08-30 2021-06-21 엘지디스플레이 주식회사 Pyrene compound and organic light emitting diode device comprising the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998617A (en) * 1997-04-02 1999-12-07 Gentex Corporation Electrochromic compounds

Also Published As

Publication number Publication date
CN106554322A (en) 2017-04-05

Similar Documents

Publication Publication Date Title
CN106554319B (en) Quinazoline group-containing derivative and application thereof
CN111662225A (en) Organic compound containing pyrene and application thereof
CN106554352B (en) Polycyclic aromatic hydrocarbon derivative containing naphthyridine group and application thereof
CN110256428B (en) Compound, OLED display panel and display device
CN104513662A (en) Organic light-emitting material and application thereof
CN106554322B (en) Phenazine derivative and application thereof in organic electroluminescent device
CN104650032A (en) Acridine derivatives, and preparation method and application thereof
CN104513247A (en) Benzo [c] benzo [3,4] carbazol derivatives and uses
CN103788087B (en) Anthracene derivatives containing imidazo[1,2,a]pyridine group and applications thereof in OLEDs
CN104673276A (en) Organic luminescent material and application thereof
CN112724136A (en) Organic compound, electroluminescent material and application thereof
CN113402507A (en) Triphenylene derivative, light-emitting device material, and light-emitting device
CN107663169B (en) 6H-naphtho [2,1,8,7-klmn ] acridine derivative and application thereof
CN104513660A (en) Organic luminescence material and applications thereof
CN111303056B (en) Phenazine group-substituted polycyclic aromatic hydrocarbon derivative and application thereof
CN111233840A (en) Quinoxaline derivative and application thereof in organic light-emitting device
CN104649954A (en) Phenanthrocarbazole derivative and application of phenanthrocarbazole derivative in organic electroluminescence devices
CN109309166B (en) Organic electroluminescent device and anthracene compound containing 2,6,9, 10-tetra-substitution
CN110964009B (en) Compound containing phenanthroline structure, application thereof and organic electroluminescent device
CN104672211A (en) Benzacridine derivatives, and preparation method and applications thereof
CN111187225B (en) Condensed ring aromatic hydrocarbon derivative with quinoxaline group and application thereof
CN111675714A (en) Organic electroluminescent compound with balanced carrier transmission performance and application thereof
CN104513192A (en) Benzoanthra[9,1-bc]carbazole derivative and applications thereof
CN104693174B (en) Benzacridine derivant, its preparation method and application thereof
CN109678799B (en) Dihydrobenzandazole compound, organic electroluminescent device and display device

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant